Cencora, Inc. $COR Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. lessened its holdings in shares of Cencora, Inc. (NYSE:COR) by 2.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,523 shares of the company’s stock after selling 1,762 shares during the period. TD Waterhouse Canada Inc.’s holdings in Cencora were worth $26,407,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GC Wealth Management RIA LLC bought a new position in shares of Cencora in the second quarter valued at approximately $332,000. Janney Montgomery Scott LLC raised its position in Cencora by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 45,984 shares of the company’s stock worth $13,789,000 after acquiring an additional 2,058 shares in the last quarter. Raleigh Capital Management Inc. lifted its holdings in Cencora by 37.2% in the 2nd quarter. Raleigh Capital Management Inc. now owns 472 shares of the company’s stock valued at $141,000 after acquiring an additional 128 shares during the last quarter. Capital Investment Advisors LLC boosted its position in shares of Cencora by 9.7% during the 2nd quarter. Capital Investment Advisors LLC now owns 1,050 shares of the company’s stock valued at $315,000 after purchasing an additional 93 shares in the last quarter. Finally, Truist Financial Corp raised its holdings in shares of Cencora by 1.2% in the 2nd quarter. Truist Financial Corp now owns 390,665 shares of the company’s stock worth $117,141,000 after purchasing an additional 4,466 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 1.7%

NYSE COR opened at $350.13 on Thursday. The company has a market capitalization of $67.92 billion, a PE ratio of 44.04, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. Cencora, Inc. has a 1-year low of $237.71 and a 1-year high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The firm’s fifty day simple moving average is $347.96 and its 200-day simple moving average is $323.25.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the business posted $3.34 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 20,316 shares of company stock worth $7,151,265. Company insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Bank of America decreased their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. UBS Group lifted their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $393.08.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.